Colorectal Surgery Unit, Hospital Arnau de Vilanova, Valencia, Spain.
Department of General and Digestive Surgery, Hospital Universitario La Ribera, Alzira, Valencia, Spain.
Eur J Surg Oncol. 2021 Jul;47(7):1541-1551. doi: 10.1016/j.ejso.2021.02.020. Epub 2021 Feb 26.
D3-Lymphadenectomy, together with complete mesocolic excision (CME), were introduced to provide oncological results after right colon cancer. The aim of this systematic review with meta-analysis was to assess the short and long-term outcomes of right-sided hemicolectomy with CME + D3 as compared with classic right hemicolectomy. Secondary aims included the prevalence of D3-metastasis and skip metastasis when performing CME + D3.
A systematic review with meta-analysis was conducted, according to PRISMA methodology.
29 studies were enrolled (2592 patients). No differences were accounted in morbidity variables associated with the measured techniques. CME + D3 was significantly associated with a greater distance between the tumour and the closest vascular tie, a longer colonic resection, a wider resection of mesentery and an increased number of harvested lymph nodes. Regarding to long-terms outcomes, we found a significant decrease in local recurrence in patients undergoing CME + D3 (HR:0.17) and a significant improvement in 3-year and 5-year overall survival rates (HR:0.53 vs. HR:0.57, respectively), as well as an improving survival in patients with stage II and III disease. Overall prevalence of patients with lymphatic metastases in D3-territory was of 8.6% and 2.2% of skip metastases.
CME + D3 is a feasible surgical procedure that allows to obtain specimens with higher quality oncological resection, without greater associated morbidity, thus improving survival in patients with stage II and III right colon cancer.
D3 淋巴结清扫术与完整结肠系膜切除术(CME)联合应用于右半结肠癌,旨在提供更好的肿瘤学结果。本系统评价和荟萃分析旨在评估 CME+D3 右半结肠切除术与经典右半结肠切除术的短期和长期结果。次要目标包括在施行 CME+D3 时 D3 转移和跳跃转移的发生率。
根据 PRISMA 方法进行系统评价和荟萃分析。
共纳入 29 项研究(2592 例患者)。与所测量技术相关的发病率变量无差异。CME+D3 与肿瘤与最近血管结扎之间的距离更大、结肠切除更长、肠系膜切除更广泛以及淋巴结采集数量更多相关。关于长期结果,我们发现 CME+D3 组患者局部复发率显著降低(HR:0.17),3 年和 5 年总生存率显著提高(HR:0.53 比 HR:0.57),且 II 期和 III 期疾病患者的生存率也有所提高。D3 区域淋巴结转移的患者总体发生率为 8.6%,跳跃转移的发生率为 2.2%。
CME+D3 是一种可行的手术方法,可获得更高质量的肿瘤学切除标本,而不会增加相关发病率,从而提高 II 期和 III 期右半结肠癌患者的生存率。